Johnson & Johnson is executing well fundamentally, and its conglomerate structure continues to pay an ever-increasing dividend.

Its pharmaceutical operations have a number of commercial gems, but there is even more to be excited about within the pipeline, too.

Litigation risk may be hurting the stock, but we like the company's dividend coverage and shares have meaningful valuation support at present levels.

READ FULL ARTICLE HERE